Pfizer inked a deal with the Bill & Melinda Gates Foundation to roll out a long-acting contraceptive in 69 of the world's poorest countries.
A decade-long class action lawsuit against Pfizer over alleged off-label Neurontin marketing is finally wrapping up, with U.S. District Judge Patti Saris approving a $325 million settlement on Monday.
In an investigative piece published this weekend, the New York Times fingered Pfizer lawyers for wining, dining and otherwise influencing an attorney general to get a favorable lawsuit settlement. Pfizer says the back-and-forth was all aboveboard and part of routine legal negotiations.
The BBC has some numbers sourced from GlobalData showing that 9 out of 10 Big Pharma companies do in fact spend more on marketing than on R&D. In some cases, that's twice as much.
Hiring and keeping good employees is as much of a challenge in the drug business as it is anywhere else. So, it's always nice to know that would-be job seekers think your company is swell. Here's the latest gauge of drugmakers' status in the world of recruiting.
We have a winner. In a two-horse race to grab the first-ever U.S. approval for a meningitis B vaccine, Pfizer has emerged victorious, nabbing the FDA's blessing Wednesday.
Pfizer CEO Ian Read makes no apologies for his interest in working a deal to move his tax home overseas. Despite the U.S. government's attempt to discourage tax inversions--like the one Pfizer would have achieved by buying AstraZeneca--Read says he's not deterred.
The prospects for Remoxy, the twice-rejected, investigational, extended-release oral formulation of oxycodone, look bleak. Pfizer is pulling out of a partnership with Durect to commercialize the candidate, after reviewing the results of 5 clinical trials conducted in response to the FDA's second complete response letter, issued in 2011.
Pfizer is popping the confetti on earnings that beat analysts' expectations, bolstered by sales of cancer drugs and growth in emerging markets. But as for that much-talked about deal with AstraZeneca? No word for now.
Pfizer had hung on to high hopes for the drug Remoxy long after the tamper-resistant pain therapy endured its second rejection at the hands of the FDA in 2011. It even officially re-upped for the late-stage comeback try last fall, committing to see it through a third try. But today Pain Therapeutics says that the pharma giant has finally thrown in the towel, handing back rights to the long-delayed treatment and washing its hands of any further development work.